Company intelligence / Profile preview

Nadianbio

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Nadian Bio is a pre-clinical stage biotechnology company focused on developing next-generation precision oncology therapeutics. The company leverages a proprietary functional genomics platform to identify and target vulnerabilities in the DNA damage response (DDR) pathways of cancer cells. By exploiting synthetic lethal relationships, Nadian Bio aims to create highly selective small molecule inhibitors for patients with specific genetic alterations, such as those in the Fanconi Anemia or BRCA pathways. Headquartered in Cambridge, Massachusetts, the company is built on foundational research from leading academic institutions in the field of DNA repair.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nadianbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nadianbio.

Explore the full profile